FSD Pharma completes dosing of first cohort in Phase I clinical trial of Lucid-MS
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
PredOmix has developed a novel blood test that can detect about 32 cancers in both men and women with 98 percent accuracy
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
The combination will support clients in getting their end-to-end discovery and development programs delivered.
Bourgoin early development hub broadens offerings for oral solid dose formulations
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics and other self-administered therapies
Subscribe To Our Newsletter & Stay Updated